The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of The Medicines Company's 2013 cardiovasular sales performance.
Potential first-in-class treatment moves closer to EU approval. Novartis has been granted a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ... Novartis picked up Leqvio following its $9.7bn
The three from this year’s list are: Valrox, which if approved, would become the first gene therapy for any form of haemophilia; Inclisiran, from The Medicines Company, which could become ... 8. Inclisiran from The Medicines Company (now a Novartis
The announcement was made on the same day that the company officially opened its new headquarters in White City, London. ... Novartis acquired inclisiran from The Medicines Company, after a completing a $9.7bn takeover of the company.
According to the company, the momentum of the neprilysin inhibitor was driven by a higher demand in ambulatory settings. ... These new drugs are expected to continue to drive growth into 2020 – newly acquired cholesterol drug inclisiran, gained from
Novartis gained inclisiran from its $9.7bn acquisition of the drug's developer The Medicines Company, which completed last week. ... watchdog NICE once it receives approval from the European Medicines Agency (EMA).
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....